Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

about

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

Item

http://www.wikidata.org/entity/Q42045329

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

@en

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

@nl

type

Item

label

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

@en

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

@nl

prefLabel

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

@en

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

@nl

P1476

Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors

@en

P2093

Christopher O Phillips

http://www.w3.org/2001/XMLSchema#string

P2860

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: de

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

HFSA 2010 Comprehensive Heart Failure Practice Guideline.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis.

Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

P304

E309-11

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.110366

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

183

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50595720

http://www.w3.org/2001/XMLSchema#string

P698

21422130

http://www.w3.org/2001/XMLSchema#string

P932

3071405

http://www.w3.org/2001/XMLSchema#string